Inhibition of Dendritic Cell Generation and Function by Serum from Prostate Cancer Patients: Correlation with Serum-Free PSA

  • Maryam Aalamian-Matheis
  • Gurkamal S. Chatta
  • Michael R. Shurin
  • Edith Huland
  • Hartwig Huland
  • Galina V. Shurin
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 601)


Tumor produces a number of immunosuppressive factors that block maturation of dendritic cells (DCs). Here, we demonstrated that endogenous factors presented in the serum of patients with prostate cancer (CaP) inhibited the generation of functionally active DCs from CD14+ monocytes in vitro. We have shown a significant inhibitory potential of serum obtained from patients with CaP and benign prostate hyperplasia benign prostatic hyperplasia (BPH) when compared with serum from healthy volunteers. As assessed by flow cytometry, expression of CD83, CD86, and CD40 molecules was strongly inhibited by CaP and BPH serum. In addition, these DCs were weak stimulators of allogeneic T cell proliferation when compared with DCs produced in the presence of healthy volunteer serum. Statistical analysis of the results revealed a positive relationship between the inhibition of expression of DC markers CD83 and CD80 and the levels of serum-free prostate-specific antigen (PSA). These data suggest that the DC system may be impaired in CaP patients.


Prostate Cancer Prostate Specific Antigen Benign Prostatic Hyperplasia Benign Prostatic Hyperplasia Patient Dendritic Cell Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aalamian, M., Pirtskhalaishvili, G., Nunez, A., Esche, C., Shurin, G.V., Huland, E., Huland, H. and Shurin, M.R. (2001) Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 46, 68–75.CrossRefPubMedGoogle Scholar
  2. Aalamian, M., Tourkova, I.L., Chatta, G.S., Lilja, H., Huland, E., Huland, H., Shurin, G.V. and Shurin, M.R. (2003) Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J. Urol. 170, 2026–2030.CrossRefPubMedGoogle Scholar
  3. Armstrong, T.D., Pulaski, B.A. and Ostrand-Rosenberg, S. (1998) Tumor antigen presentation: changing the rules. Cancer Immunol. Immunother. 46, 70–74.CrossRefPubMedGoogle Scholar
  4. Arya, M., Bott, S.R., Shergill, I.S., Ahmed, H.U., Williamson, M. and Patel, H.R. (2006) The metastatic cascade in prostate cancer. Surg. Oncol. 23, 77–83.Google Scholar
  5. Becker, Y. (1992) Anticancer role of dendritic cells (DC) in human and experimental cancers – a review. Anticancer Res. 12, 511–520.PubMedGoogle Scholar
  6. Catalona, W.J., Partin, A.W., Slawin, K.M., Brawer, M.K., Flanigan, R.C., Patel, A., Richie, J.P., deKernion, J.B., Walsh, P.C., Scardino, P.T., Lange, P.H., Subong, E.N., Parson, R.E., Gasior, G.H., Loveland, K.G. and Southwick, P.C. (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279, 1542–1547.CrossRefPubMedGoogle Scholar
  7. Christensson, A., Bjork, T., Nilsson, O., Dahlen, U., Matikainen, M.T., Cockett, A.T., Abrahamsson, P.A. and Lilja, H. (1993) Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J. Urol. 150, 100–105.PubMedGoogle Scholar
  8. Christensson, A., Laurell, C.B. and Lilja, H. (1990) Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194, 755–763.CrossRefPubMedGoogle Scholar
  9. Colaco, C.A. (1999a) DC-based cancer immunotherapy: the sequel. Immunol. Today 20, 197–198.CrossRefPubMedGoogle Scholar
  10. Colaco, C.A. (1999b) Why are dendritic cells central to cancer immunotherapy? Mol. Med. Today 5, 14–17.CrossRefPubMedGoogle Scholar
  11. Comuzzi, B. and Sadar, M.D. (2006) Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. Cell Sci. 3, 61–81.Google Scholar
  12. Diamandis, E.P. and Yu, H. (1997) Nonprostatic sources of prostate-specific antigen. Urol. Clin. North. Am. 24, 275–282.CrossRefPubMedGoogle Scholar
  13. Elabbady, A.A. and Khedr, M.M. (2006) Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml. Int. Urol. Nephrol. 38, 553–557.CrossRefPubMedGoogle Scholar
  14. Frassica, F.J., Gitelis, S. and Sim, F.H. (1992) Metastatic bone disease: general principles, pathophysiology, evaluation, and biopsy. Instr. Course Lect. 41, 293–300.PubMedGoogle Scholar
  15. Hall, C.L., Bafico, A., Dai, J., Aaronson, S.A. and Keller, E.T. (2005) Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 65, 7554–7560.PubMedGoogle Scholar
  16. Harris, D.T., Matyas, G.R., Gomella, L.G., Talor, E., Winship, M.D., Spitler, L.E. and Mastrangelo, M.J. (1999) Immunologic approaches to the treatment of prostate cancer. Semin. Oncol. 26, 439–447.PubMedGoogle Scholar
  17. Healy, C.G., Simons, J.W., Carducci, M.A., DeWeese, T.L., Bartkowski, M., Tong, K.P. and Bolton, W.E. (1998) Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 32, 109–119.CrossRefPubMedGoogle Scholar
  18. Herr, H.W. (1980) Suppressor cells in immunodepressed bladder and prostate cancer patients. J. Urol. 123, 635–639.PubMedGoogle Scholar
  19. Huang, A.Y.C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. and Levitsky, H. (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961–965.CrossRefPubMedGoogle Scholar
  20. Ivshina, A.V., Zhumagazin Zh, D., Zabotina, T.N., Matveev, B.P. and Kadagidze, Z.G. (1995) Effect of the spread of the process and treatment on the phenotype of peripheral blood lymphocytes in patients with prostatic cancer. Urologiia. i. Nefrologiia 9, 36–38.Google Scholar
  21. Jung, K., Brux, B., Lein, M., Rudolph, B., Kristiansen, G., Hauptmann, S., Schnorr, D., Loening, S.A. and Sinha, P. (2000) Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. Clin. Chem. 46, 47–54.PubMedGoogle Scholar
  22. Landis, S.H., Murray, T., Bolden, S. and Wingo, P.A. (1999) Cancer statistics, 1999. CA Cancer J. Clin. 49, 8–31.CrossRefPubMedGoogle Scholar
  23. Li, N., Qin, H., Li, X., Zhou, C., Wang, D., Ma, W., Lin, C., Zhang, Y., Wang, S. and Zhang, S. (2006) Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. J. Clin. Immunol. 27, 117–130.CrossRefPubMedGoogle Scholar
  24. Lilja, H. (1993) Structure, function, and regulation of the enzyme activity of prostate- specific antigen. World J. Urol. 11, 188–191.CrossRefPubMedGoogle Scholar
  25. Lotze, M.T. (1997) Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer [editorial; comment]. Ann. Surg. 226, 1–5.CrossRefPubMedGoogle Scholar
  26. McGregor, A.R., Moore, M.L., Bailey, R.R., Robson, R.A. and Lynn, K.L. (1990) Disseminated prostatic carcinoma presenting with acute interstitial nephritis and microangiopathic haemolytic anaemia. Aust. N. Z. J. Med. 20, 170–172.PubMedGoogle Scholar
  27. Mohamedali, K.A., Poblenz, A.T., Sikes, C.R., Navone, N.M., Thorpe, P.E., Darnay, B.G. and Rosenblum, M.G. (2006) Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res. 66, 10919–10928.CrossRefPubMedGoogle Scholar
  28. Oesterling, J.E. (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145, 907–923.PubMedGoogle Scholar
  29. Polascik, T.J., Oesterling, J.E. and Partin, A.W. (1999) Prostate specific antigen: a decade of discovery–what we have learned and where we are going. J. Urol. 162, 293–306.CrossRefPubMedGoogle Scholar
  30. Ragde, H., Cavanagh, W.A. and Tjoa, B.A. (2004) Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J. Urol. 172, 2532–2538.CrossRefPubMedGoogle Scholar
  31. Salgaller, M.L., Lodge, P.A., McLean, J.G., Tjoa, B.A., Loftus, D.J., Ragde, H., Kenny, G.M., Rogers, M., Boynton, A.L. and Murphy, G.P. (1998) Report of immune monitoring of prostate cancer patients undergoing T cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen. Prostate 35, 144–151.CrossRefPubMedGoogle Scholar
  32. Shamdas, G.J., Ahmann, F.R., Matzner, M.B. and Ritchie, J.M. (1993) Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 71, 3594–3600.Google Scholar
  33. Shurin, G.V., Aalamian, M., Pirtskhalaishvili, G., Bykovskaia, S., Huland, E., Huland, H. and Shurin, M.R. (2001) Human prostate cancer blocks the generation of endritic cells from CD34+ hematopoietic progenitors. Eur. Urol. 39 (suppl), 37–40.CrossRefPubMedGoogle Scholar
  34. Shurin, M.R. (1996) Dendritic cells presenting tumor antigen. Cancer Immunol. Immunother. 43, 158–164.CrossRefPubMedGoogle Scholar
  35. Simons, J.W., Mikhak, B., Chang, J.F., DeMarzo, A.M., Carducci, M.A., Lim, M., Weber, C.E., Baccala, A.A., Goemann, M.A., Clift, S.M., Ando, D.G., Levitsky, H.I., Cohen, L.K., Sanda, M.G., Mulligan, R.C., Partin, A.W., Carter, H.B., Piantadosi, S., Marshall, F.F. and Nelson, W.G. (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160–5168.PubMedGoogle Scholar
  36. Slovin, S.F., Kelly, W.K. and Scher, H.I. (1998) Immunological approaches for the treatment of prostate cancer. Semin. Urol. Oncol. 16, 53–59.PubMedGoogle Scholar
  37. Speiser, D.E., Miranda, R., Zakarian, A., Bachmann, M.F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R.M. and Ohashi, P.S. (1997) Self antigens expressed by soild tumors do not efficiently stimulate naïve or activated T cells: implications for immunotherapy. J. Exp. Med. 186, 645–653.CrossRefPubMedGoogle Scholar
  38. Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S. and Redwine, E. (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909–916.CrossRefPubMedGoogle Scholar
  39. Stephan, C., Jung, K., Lein, M., Sinha, P., Schnorr, D. and Loening, S.A. (2000) Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 9, 1133–1147.PubMedGoogle Scholar
  40. Troy, A., Davidson, P., Atkinson, C. and Hart, D. (1998) Phenotypic characterization of the dendritic cell infiltrate in prostate cancer. J. Urol. 160, 214–219.CrossRefPubMedGoogle Scholar
  41. Troy, A., Davidson, P., Atkinson, C. and Hart, D. (1999) Renal cell carcinoma and prostate cancer inhibit dendritic cell activation. Aust. N. Z. J. Surg. 69, A111–A112.Google Scholar
  42. Williams, S.A., Singh, P., Isaacs, J.T. and Denmeade, S.R. (2006) Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 67, 312–329.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Maryam Aalamian-Matheis
    • 1
  • Gurkamal S. Chatta
    • 2
  • Michael R. Shurin
    • 3
  • Edith Huland
    • 4
  • Hartwig Huland
    • 4
  • Galina V. Shurin
    • 5
  1. 1.Department of MedicineJohns Hopkins UniversityBaltimoreUSA
  2. 2.Department of MedicineUniversity of PittsburghPittsburghUSA
  3. 3.Department of Pathology and ImmunologyUniversity of PittsburghPittsburghUSA
  4. 4.Department of UrologyUniversity Clinics Hamburg-EppendorfHamburgGermany
  5. 5.Department of PathologyUniversity of PittsburghPittsburghUSA

Personalised recommendations